• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: U.K. leads Europe in capital raised and pipeline of products

Report: U.K. leads Europe in capital raised and pipeline of products

October 9, 2014
CenterWatch Staff

The U.K. biotech ecosystem continues to flourish based on strong fundamentals, according to a new State of the Nation report by Ernst & Young and the BioIndustry Association (BIA), a trade association for innovative enterprises involved in U.K. bioscience.

The report shows:

  • The U.K. leads Europe in the total amount of innovation capital raised ($1.2 billion), as well as number of financing rounds (36) for the first half of 2014
  • 2014 is set to be a banner year, as the total for the first half of 2014 already has surpassed the total of $776.8 million of innovation capital raised in 2013
  • European life sciences financing in the first half of 2014 already has surpassed the $3.4 billion raised in 2013
  • The U.K. remains the largest bioscience cluster in Europe, developing over 450 product candidates in 2013.

Steve Bates, CEO of the BIA, said, “2014 has been a strong and confident year for U.K. life science companies. This year, for the first time in many years, we’ve seen IPOs return to the sector.  Companies large and small, academia, research charities, new institutions and the NHS now mix together in our ecosystem to make it one of the most vibrant and dynamic in the world.”

Ian Oliver, executive director of assurance at EY said, “Since our last U.K. report, I’m delighted to say that the life sciences industry has started to make up much of the ground it lost during the financial crisis, in both the U.K. and on a global scale. In early 2014, the U.K. AIM and main markets began to host U.K. life sciences company admissions, taking advantage of the positive momentum developed by U.S. investors in 2013, including one of the largest biotech IPO fundraisings seen on the London market by Circassia.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing